AIMS: To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF). METHODS AND RESULTS: We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model to combine quantitative data and rated the quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation). From 441 total citations in MEDLINE, EMBASE, and CENTRAL (December 2018), we identified nine trials evaluating 1358 participants. Six trials compared vernakalant to placebo, two trials compared vernakalant to ibutilide, and one trial compared vernakalant to amiodarone. We found significant methodological bias in four trials. For conversion within 90 min, vernakalant was superior to placebo [50% conversion, risk ratio (RR) 5.15; 95% confidence interval (CI); 2.24-11.84, I2 = 91%], whereas we found no significant difference in conversion when vernakalant was compared with an active drug (56% vs. 24% conversion, RR 2.40; 95% CI 0.76-7.58, I2 = 94). Sinus rhythm was maintained at 24 h in 85% (95% CI 80-88%) of patients who converted acutely with vernakalant. Overall, we judged the quality of evidence for efficacy to be low based on inconsistency and suspected publication bias. There was no significant difference in the risk of significant adverse events between vernakalant and comparator (RR 0.95; 95% CI 0.70-1.28, I2 = 0, moderate quality evidence). Vernakalant is safe and effective for rapid and durable restoration of sinus rhythm in patients with recent-onset AF. CONCLUSION: Vernakalant should be a first line option for the pharmacological cardioversion of patients with haemodynamically stable recent-onset AF without severe structural heart disease. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF). METHODS AND RESULTS: We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model to combine quantitative data and rated the quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation). From 441 total citations in MEDLINE, EMBASE, and CENTRAL (December 2018), we identified nine trials evaluating 1358 participants. Six trials compared vernakalant to placebo, two trials compared vernakalant to ibutilide, and one trial compared vernakalant to amiodarone. We found significant methodological bias in four trials. For conversion within 90 min, vernakalant was superior to placebo [50% conversion, risk ratio (RR) 5.15; 95% confidence interval (CI); 2.24-11.84, I2 = 91%], whereas we found no significant difference in conversion when vernakalant was compared with an active drug (56% vs. 24% conversion, RR 2.40; 95% CI 0.76-7.58, I2 = 94). Sinus rhythm was maintained at 24 h in 85% (95% CI 80-88%) of patients who converted acutely with vernakalant. Overall, we judged the quality of evidence for efficacy to be low based on inconsistency and suspected publication bias. There was no significant difference in the risk of significant adverse events between vernakalant and comparator (RR 0.95; 95% CI 0.70-1.28, I2 = 0, moderate quality evidence). Vernakalant is safe and effective for rapid and durable restoration of sinus rhythm in patients with recent-onset AF. CONCLUSION:Vernakalant should be a first line option for the pharmacological cardioversion of patients with haemodynamically stable recent-onset AF without severe structural heart disease. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jason G Andrade; Atul Verma; L Brent Mitchell; Ratika Parkash; Kori Leblanc; Clare Atzema; Jeff S Healey; Alan Bell; John Cairns; Stuart Connolly; Jafna Cox; Paul Dorian; David Gladstone; M Sean McMurtry; Girish M Nair; Louise Pilote; Jean-Francois Sarrazin; Mike Sharma; Allan Skanes; Mario Talajic; Teresa Tsang; Subodh Verma; D George Wyse; Stanley Nattel; Laurent Macle Journal: Can J Cardiol Date: 2018-11 Impact factor: 5.223
Authors: David Fedida; Peter M R Orth; Janet Y C Chen; Shunping Lin; Bertrand Plouvier; Grace Jung; Alan M Ezrin; Gregory N Beatch Journal: J Cardiovasc Electrophysiol Date: 2005-11
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld Journal: Europace Date: 2016-08-27 Impact factor: 5.214
Authors: Peter R Kowey; Paul Dorian; L Brent Mitchell; Craig M Pratt; Denis Roy; Peter J Schwartz; Jerzy Sadowski; Dorota Sobczyk; Andrzej Bochenek; Egon Toft Journal: Circ Arrhythm Electrophysiol Date: 2009-12
Authors: Denis Roy; Craig M Pratt; Christian Torp-Pedersen; D George Wyse; Egon Toft; Steen Juul-Moller; Tonny Nielsen; S Lind Rasmussen; Ian G Stiell; Benoit Coutu; John H Ip; Edward L C Pritchett; A John Camm Journal: Circulation Date: 2008-03-10 Impact factor: 29.690
Authors: Paul Dorian; Arnold Pinter; Iqwal Mangat; Victoria Korley; Suzan S Cvitkovic; Gregory N Beatch Journal: J Cardiovasc Pharmacol Date: 2007-07 Impact factor: 3.105
Authors: Alexander Simon; Jan Niederdoeckl; Ekaterini Skyllouriotis; Nikola Schuetz; Harald Herkner; Christoph Weiser; Anton N Laggner; Hans Domanovits; Alexander O Spiel Journal: Europace Date: 2017-02-01 Impact factor: 5.214
Authors: Beata Ceynowa-Sielawko; Maciej T Wybraniec; Aleksandra Topp-Zielińska; Aleksander Maciąg; Dawid Miśkowiec; Paweł Balsam; Maciej Wójcik; Wojciech Wróbel; Michał M Farkowski; Edyta Ćwiek-Rębowska; Krzysztof Ozierański; Robert Błaszczyk; Karolina Bula; Tomasz Dembowski; Michał Peller; Bartosz Krzowski; Wojciech Wańha; Marek Koziński; Jarosław D Kasprzak; Hanna Szwed; Katarzyna Mizia-Stec; Marek Szołkiewicz Journal: Int J Environ Res Public Health Date: 2022-04-17 Impact factor: 3.390